Involving A Modified Enzyme (e.g., Abzyme, Recombinant, Chemically Altered, Etc.) Patents (Class 435/7.6)
  • Patent number: 9585975
    Abstract: The present invention relates to MRI based imaging. In particular, the present invention provides MRI contrast agents targeted to a HaloTag protein with tunable relaxation properties thereby providing optimal relaxivity for low field strength imaging and the other optimal relaxivity for high field strength imaging. Moreover, the MRI contrast agents are used to detect gene expression (of a gene of interest) in real time in vivo, to detect changes in gene expression (of a gene of interest) over time in, for example, an individual organism, to detect gene expression changes (of a gene of interest) in response to therapeutics, in cell labeling for MR imaging, in clinical diagnostics, and in theranostics.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: March 7, 2017
    Assignee: Northwestern University
    Inventors: Thomas J. Meade, Renee C. Strauch, Luke F. Vistain
  • Patent number: 9518081
    Abstract: The invention relates to a method for altering the conformational diversity of a first repertoire of polypeptide ligands, comprising a plurality of polypeptides comprising at least two reactive groups separated by a loop sequence covalently linked to a molecular scaffold which forms covalent bonds with said reactive groups, to produce a second repertoire of polypeptide ligands, comprising assembling said second repertoire from the polypeptides and structural scaffold of said first repertoire, incorporating one of the following alterations: (a) altering at least one reactive group; or (b) altering the nature of the molecular scaffold; or (c) altering the bond between at least one reactive group and the molecular scaffold; or (d) any combination of (a), (b) or (c).
    Type: Grant
    Filed: August 12, 2010
    Date of Patent: December 13, 2016
    Assignee: BICYCLE THERAPEUTICS LIMITED
    Inventors: Gregory Paul Winter, Christian Heinis, Elise Bernard, David Loakes, Daniel Paul Teufel
  • Patent number: 9222909
    Abstract: A biosensor according to the present invention includes a first base material having an insulating surface; an adhesive layer located on the insulating surface of the first base material; and an electrode system and wiring sections fixed to the first base material via the adhesive layer. The electrode system includes top electrode layers and bottom electrode layers, and the bottom electrode layers are formed of a material having a higher conductivity than that of the top electrode layers; the electrode system includes a working electrode and a counter electrode, and also includes an enzyme reaction section located on the working electrode, the enzyme reaction section containing an enzyme and an electron acceptor; and the bottom electrode layers and the wiring sections are integral with each other.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: December 29, 2015
    Assignee: DAI NIPPON PRINTING CO., LTD.
    Inventors: Masanao Watanabe, Kenichi Ito, Makoto Ishii, Hiroshi Yoshida, Toshiaki Baba
  • Patent number: 9193984
    Abstract: Disclosed is a novel method for detecting interactions of biomolecules. More particularly, the disclosed method includes (a) preparing a cell comprising (i) a first construct comprising a bait, a first labeling material and a translocation module; and (ii) a second construct comprising a prey and a second labeling material; (b) detecting the distribution of the first construct and the second construct in the cell. the present invention provides a method capable of detecting bindings and interactions occurring in a living cell in real time, and a method for screening a material that alters the binding and the interaction. The method of the present invention overcomes the disadvantages including inaccuracy and complexity of existing biomaterial interaction detection techniques. By labeling both constructs to promote accuracy, the present invention provides a novel real-time, antibody-free analysis.
    Type: Grant
    Filed: January 3, 2013
    Date of Patent: November 24, 2015
    Assignee: Korea Basic Science Institute
    Inventors: Zee Won Lee, Soo Hyun Kim
  • Publication number: 20150031744
    Abstract: The invention provides a method of determining the prognosis of cancer in a subject. The method comprises (a) obtaining a sample from the subject, (b) analyzing the sample for the expression level of a carboxypeptidase E (CPE) splice variant, and (c) correlating the expression level in the sample with the prognosis of cancer in the subject. The invention further provides a method of diagnosing cancer, methods of treatment, kits for detecting mRNA expression of a CPE-?N, and inhibitors of CPE-?N and compositions thereof.
    Type: Application
    Filed: July 22, 2014
    Publication date: January 29, 2015
    Inventors: Yoke Peng Loh, Niamh X. Cawley, Saravana Radha Krishna Murthy, Terence K. Lee
  • Publication number: 20150010525
    Abstract: The present invention describes an unbiased catalytic tagging system to search for target substrates. Identification of substrates for specific baits is accomplished by utilizing an orthogonal system consisting of an E1 activating enzyme, an E2 ubiquitin-like conjugating enzyme, and baits that are fused to the E2 ubiquitin-like conjugating enzyme. The present invention thus reveals important mutually antagonistic substrates of specific baits.
    Type: Application
    Filed: January 23, 2013
    Publication date: January 8, 2015
    Inventors: James A. Wells, Min Zhuang
  • Publication number: 20150010584
    Abstract: The present invention is related to compositions and methods to stimulate the immune system. For example, antigen-specific antibodies may be produced by stimulating B cell populations with specific antigenic compounds, such as an adjuvant comprising a macromolecule capable of activating a Toll-Like receptor (TLR). For example, a BCR adapter IgM (BCRAM) is described to exemplify delivery of autoantigens to polyclonal B cell populations resulting in immunoactivation by TLR activation. Alternatively, a compound is described that inhibits TLR activation.
    Type: Application
    Filed: June 26, 2014
    Publication date: January 8, 2015
    Inventors: Ann Marshak-Rothstein, Krishna Moody
  • Publication number: 20140378324
    Abstract: Disclosed herein are mutated RAF and KSR nucleic acids and polypeptides. Also disclosed are methods of using the mutated RAF and KSR to inhibit the dimerization of RAF/RAF and RAF/KSR. Also disclosed are methods of using the mutated RAF and KSR to screen for inhibitors of dimerization.
    Type: Application
    Filed: December 20, 2013
    Publication date: December 25, 2014
    Applicants: MOUNT SINAI HOSPITAL, UNIVERSITE DE MONTREAL
    Inventors: HUGO LAVOIE, Malha Sahmi, Marc Therrien, Thanashan Rajakulendran, Frank Sicheri
  • Patent number: 8906637
    Abstract: The present invention provides method and compositions for detecting target molecules present on cells and tissues. In particular, the methods involve adding primary antibodies such as scFv-targeted lactamase that are directed against a target of interest (e.g., cancer markers) to a tissue sample, followed by adding a lactam-containing compound and finally a lactamase reporter system. In some preferred embodiments, the lactamase reporters are fluorescent reporters that bind to the test tissue. In some particularly preferred embodiments, the test tissue contains at least once cancer cell and/or at least one cancer-associated marker.
    Type: Grant
    Filed: September 9, 2005
    Date of Patent: December 9, 2014
    Assignee: Danisco US Inc.
    Inventor: Steven W. Sherwood
  • Patent number: 8865421
    Abstract: Methods and genetic constructs are provided for detecting the binding of nuclear hormone receptors to a coactivator/corepressor. The methods employ enzyme fragment complementation using fragments of ?-galactosidase as the detection system. Cells are transformed to express the large fragment of ?-galactosidase fused to a member of the complex with NHR for initiation of transcription and have it localized in the nucleus and to express the small fragment of ?-galactosidase fused to the nuclear hormone receptor for binding to the member upon stimulation with a ligand.
    Type: Grant
    Filed: June 23, 2009
    Date of Patent: October 21, 2014
    Assignee: DiscoveRx Corporation
    Inventors: Thomas S. Wehrman, Chin Yee Loh, Mahesh Mathrubutham, Keith R. Olson
  • Patent number: 8859266
    Abstract: The present disclosure encompasses systems, and their methods of use, for detecting a target analyte. The systems include a first and second oligonucleotide probe that associate together to form a complex that binds to a target analyte; a cleavable reporter molecule that binds to the complex; and cleaving agent.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: October 14, 2014
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Yuliva V. Gerasimova, Dmitry M. Kolpashchikov
  • Publication number: 20140271453
    Abstract: Provided are methods of diagnosing lung cancer, particularly at an early stage, such as stage I, by detecting the presence and/or amount of at least four biomarkers of lung cancer in a sample from a subject as well as determining the number of smoking pack years for the subject. The methods and biomarkers may be used to develop an accurate prognosis for a patient having lung cancer or suspected of having lung cancer or accurately diagnose a subject having or suspected of having lung cancer. The methods and biomarkers may be used to identify and/or classify a patient as a candidate for lung cancer treatment therapy.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Inventors: Barry L. Dowell, Philip M. Hemken
  • Patent number: 8835125
    Abstract: Disclosed are compositions and methods for the labeling of two or more targets with different labels. Specifically, disclosed are compositions for biotin and the protection of biotin within multilabel assays which employ the biotin-biotin binding protein binding relationship for each distinct label in relation to targets such as nucleic acids, polypeptides, antibodies or cells. These multilabel assays are enabled through the use of biotin with desthiobiotin, orthogonal protecting schemes for biotin, or a combination of the approaches.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: September 16, 2014
    Assignee: Affymetrix, Inc.
    Inventors: Robert G. Kuimelis, Glenn H. McGall, Stephen P. A. Fodor
  • Publication number: 20140234287
    Abstract: Methods for treating cardiovascular disease, and in particular heart failure, are provided comprising administering a therapeutically effective amount of a modulator of SERCA2a post-translation modification such as SUMOylation or acetylation. Also provided are methods of treating cardiovascular disease by inhibiting SERCA2a degradation. Further provided are methods of diagnosing a propensity to develop heart failure comprising determining if a SERCA2a mutant is present or determining the level of expression of SUMO1 in cardiomyocytes. The disclosure also provides methods of screening for therapeutics that modulate the post-translational modification of SERCA2a, such as by modulating post-translational SUMOylation and/or acetylation.
    Type: Application
    Filed: July 13, 2012
    Publication date: August 21, 2014
    Applicant: Icahn School of Medicine at Mount Sinai
    Inventors: Roger Joseph Hajjar, Chang Won Kho, Ah Young Lee
  • Patent number: 8759063
    Abstract: Disclosed are DNA polymerases having increased reverse transcriptase efficiency relative to a corresponding, unmodified polymerase. The polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the DNA polymerases.
    Type: Grant
    Filed: December 5, 2012
    Date of Patent: June 24, 2014
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Keith Bauer, Thomas W. Myers, Shawn Suko
  • Patent number: 8748117
    Abstract: Probe 1 for detection and quantification of nitric oxide, which comprises two subunits 21 and 22 of soluble guanylate cyclase 2 and cGMP-visualization probes 3 respectively connected with each subunit, wherein the cGMP-visualization probe generates signal upon recognizing guanosine 3?,5?-cyclic monophospate.
    Type: Grant
    Filed: May 9, 2011
    Date of Patent: June 10, 2014
    Assignee: Japan Science and Technology Agency
    Inventors: Yoshio Umezawa, Moritoshi Sato
  • Patent number: 8722866
    Abstract: The present invention concerns methods and compositions related to type 3 phosphodiesterases (PDE3). Certain embodiments concern isolated peptides corresponding to various PDE3A isoforms and/or site-specific mutants of PDE3A isoforms, along with expression vectors encoding such isoforms or mutants. In specific embodiments, methods for identifying isoform-selective inhibitors or activators of PDE3 are provided, along with methods of use of such inhibitors or activators in the treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments.
    Type: Grant
    Filed: January 18, 2007
    Date of Patent: May 13, 2014
    Assignee: The United States of America, as Represented by the Department of Veterans Affairs
    Inventor: Matthew A. Movsesian
  • Patent number: 8722051
    Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: May 13, 2014
    Assignee: Immunex Corporation
    Inventor: Steven R. Wiley
  • Patent number: 8712749
    Abstract: The present invention relates to human Janus Kinase 3 (JAK3) and JAK3-like binding pockets. The present invention provides a computer comprising a data storage medium encoded with the structure coordinates of such binding pockets. This invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. In addition, this invention relates to methods of using the structure coordinates to screen for and design compounds, including inhibitory compounds, that bind to JAK3 protein or JAK3 protein homologues, or complexes thereof. The invention also relates to crystallizable compositions and crystals comprising JAK3 kinase domain and JAK3 kinase domain complexes with AMP-PNP.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: April 29, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Harmon Zuccola, Marc Jacobs, Lovorka Swenson, Kumkum Saxena
  • Patent number: 8710193
    Abstract: Provided is a therapeutic method exclusively targeting an amyloid ? protein (A?) having a specific turn structure of A?. Specifically provided is an antibody which specifically recognizes an amyloid ? having a turn structure at amino acids positions 22 and 23. Also provided are a medicinal composition comprising, as the active ingredient, an antibody specifically recognizing a toxic conformer of amyloid ?, an assay kit for a toxic conformer of amyloid ?, a diagnostic for Alzheimer's disease, etc.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: April 29, 2014
    Assignees: Kyoto University, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Immuno-Biological Laboratories Co., Ltd.
    Inventors: Kazuhiro Irie, Kazuma Murakami, Yuichi Masuda, Takahiko Shimizu, Takuji Shirasawa, Tsutomu Seito
  • Patent number: 8703441
    Abstract: The present invention provides and includes monoclonal antibodies (MoAbs or mAbs) specific or preferentially selective for PCBP-1 antigens, hybridoma lines that secrete these PCBP-1 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect PCBP-1 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble form of PCBP-1. The present invention further includes chimeric and humanized antibodies, processes for producing monoclonal, chimeric, and humanized antibodies using recombinant DNA technology, and their therapeutic uses, particularly in the treatment or diagnosis of cancer progression. The present invention further includes methods and kits for the immunodetection and immunotherapy of cells for samples which express PCBP-1 antigens.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: April 22, 2014
    Assignee: Alper Biotech, LLC
    Inventor: Özge Alper
  • Patent number: 8703913
    Abstract: The invention relates to an ADP binding molecule comprising a polypeptide, said polypeptide comprising amino acid sequence corresponding to at least amino acids 11 to 310 of SEQ ID NO:1, wherein said polypeptide comprises a substitution relative to SEQ ID NO:1 at amino acid C287, and wherein said polypeptide comprises a further cysteine residue for attachment of at least one reporter moiety, and wherein said polypeptide has at least 68% sequence identity to SEQ ID NO:1 at the amino acid residues corresponding to those shown in column III of table A.
    Type: Grant
    Filed: September 15, 2009
    Date of Patent: April 22, 2014
    Assignee: Medical Research Council
    Inventors: Martin Webb, Simone Kunzelmann
  • Patent number: 8691516
    Abstract: The present invention relates to a succinic acid-producing mutant microorganism that is able to utilize sucrose and glycerol simultaneously as carbon sources. More particularly, the present invention relates to a succinic acid-producing mutant microorganism that is able to utilize sucrose and glycerol simultaneously for succinic acid production, the mutant organism being obtained by relieving the mechanism of sucrose-mediated catabolite repression of glycerol in a succinic acid-producing microorganism. As described above, when the succinic acid-producing mutant microorganism is cultured, it utilizes sucrose and glycerol simultaneously so that succinic acid can be produced with high productivity in a maximum yield approaching the theoretical yield while the production of byproducts is minimized. In addition, according to the present invention, various reduced chemicals which have been produced in low yields in conventional methods can be more effectively produced.
    Type: Grant
    Filed: August 30, 2011
    Date of Patent: April 8, 2014
    Assignee: Korea Advanced Institute of Science and Technology
    Inventors: Sang Yup Lee, Jeong Wook Lee, Sol Choi, Jongho Yi
  • Patent number: 8679771
    Abstract: This invention provides general methods for selective labeling of proteins on their N-termini with synthetic peptides. The methods of this invention can be applied to the global proteomic profiling of complex mixtures of proteins and polypeptides.
    Type: Grant
    Filed: January 24, 2008
    Date of Patent: March 25, 2014
    Assignee: The Regents of the University of California
    Inventors: James A. Wells, Sami Mahrus
  • Patent number: 8673554
    Abstract: Disclosed are methods useful in multiplex cell-based assays for compound screening employing imaging instrumentation. The methods described herein offer high content information relating to the biological potency of test agents, off-target effects and cellular toxicity of potential drug candidates.
    Type: Grant
    Filed: January 15, 2009
    Date of Patent: March 18, 2014
    Assignee: Ge Healthcare UK Limited
    Inventor: Jeffrey K. Horton
  • Publication number: 20140038979
    Abstract: This invention comprises the novel compounds of formula (I) wherein n, m, t, R1, R2, R3, R4, L, Q, X, Y, Z and have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a medicine.
    Type: Application
    Filed: October 14, 2013
    Publication date: February 6, 2014
    Applicant: Janssen Pharmaceutica NV
    Inventors: Kristof VAN EMELEN, Janine Arts, Leo-Jacobus Jozef Backx, Hans Louis Jos De Winter, Sven Franciscus Anna Van Brandt, Marc Gustaaf Celine Verdonck, Lieven Meerpoel, Isabelle Noelle Constance Pilatte, Virginie Sophie Poncelet, Alexey Borisovich Dyatkin, Jimmy Arnold Viviene Van Heusden
  • Patent number: 8642283
    Abstract: The present invention provides an assay for the identification of agents which can modulate TOR-mediated phosphorylation of substrate proteins. The assays of the invention utilize substrate proteins whose amino acid sequence contains the Ser/Thr motif recognized by TOR. Naturally occurring TOR which may be used in the methods of the invention include TOR isolated from a variety of species, particularly mammalian tissues.
    Type: Grant
    Filed: May 26, 2006
    Date of Patent: February 4, 2014
    Assignee: Sanford-Burnham Medical Research Institute
    Inventor: Robert T. Abraham
  • Patent number: 8637294
    Abstract: Described herein are variants of H. jecorina CBH I, a Cel7 enzyme. The present invention provides novel cellobiohydrolases that have improved thermostability and reversibility.
    Type: Grant
    Filed: March 22, 2007
    Date of Patent: January 28, 2014
    Assignee: Danisco US Inc.
    Inventors: Anthony Day, Frits Goedegebuur, Peter Gualfetti, Colin Mitchinson, Paulien Neefe, Mats Sandgren, Andrew Shaw, Jerry Stahlberg
  • Patent number: 8586708
    Abstract: The invention relates, in part, to monovalent streptavidin compositions. The invention also relates to methods of preparing and using monovalent streptavidin compositions. In some aspects of the invention, the compositions are monovalent streptavidin with a single femtomolar biotin-binding site.
    Type: Grant
    Filed: October 28, 2005
    Date of Patent: November 19, 2013
    Assignee: Massachusetts Institute of Technology
    Inventors: Alice Y. Ting, Mark R. Howarth
  • Patent number: 8546094
    Abstract: Provided is a novel ubiquitin ligase which has linear polyubiquitination activity and can be efficiently expressed and purified. It was found out that a complex of (a) a protein having a part of HOIP and at least having a UBA region and a RING-IBR-RING region thereof, and (b) One or more kinds of proteins which individually form a complex with the above (a) is a novel ubiquitin ligase which has linear polyubiquitination activity and can be efficiently expressed and purified.
    Type: Grant
    Filed: August 6, 2010
    Date of Patent: October 1, 2013
    Assignee: Osaka University
    Inventor: Kazuhiro Iwai
  • Patent number: 8524467
    Abstract: The present invention relates to methods of identifying candidate compounds for the treatment of leukemia and diagnostic methods based on histone methylation and HoxA5 promoter activity.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: September 3, 2013
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Yi Zhang, Yuki Okada
  • Patent number: 8501426
    Abstract: The invention describes a method for assaying HCV NS3 protease activity using an NS3•4A protease molecule. The invention also provides a method for screening and identifying modulators of NS3 protease.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: August 6, 2013
    Assignee: Vertex Pharmaceutical Incorporated
    Inventor: William P. Taylor
  • Publication number: 20130143233
    Abstract: The fusion protein comprising (1) a first region comprising the amino acid sequence of SEQ ID NO: 18 and (2) a second region comprising an amino acid sequence for a polypeptide containing at least one cysteine residue for binding to other useful compound via the thiol group can be modified by chemical modification, and thus has a high catalytic ability for a luminescence activity and is highly available for general purposes.
    Type: Application
    Filed: February 8, 2013
    Publication date: June 6, 2013
    Applicant: JNC CORPORATION
    Inventors: Satoshi INOUYE, Yuiko SAHARA, Junichi SATO
  • Patent number: 8440417
    Abstract: An exemplary embodiment may be directed to a fluorescence polarization assay that screens compounds or agents for their affinity to hematopoietic prostaglandin D synthase (H-PGDS) based on their ability to displace a fluorophore-containing detection analyte bound to an enzyme comprising the primary amino acid sequence of H-PGDS. Another exemplary embodiment utilizes an enzyme having a maltose binding protein amino-acid sequence fused with an N-terminus of the enzyme.
    Type: Grant
    Filed: May 13, 2009
    Date of Patent: May 14, 2013
    Assignee: Cayman Chemical Company, Incorporated
    Inventors: Nisha Palackal, Jeffrey K. Johnson, Karie L. McGowan, Kirk W. Maxey, Gregory W. Endres
  • Patent number: 8426180
    Abstract: The invention relates to the use of carbamoyl synthetase 1 (CPS 1) as a humoral biomarker in in vitro methods for early diagnosis and detection, progress prognosis, the evaluation of the severity, and the progress evaluation of tumor diseases and chronic inflammatory intestinal diseases.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: April 23, 2013
    Assignee: B.R.A.H.M.S GmbH
    Inventors: Andreas Bergmann, Joachim Struck
  • Patent number: 8367390
    Abstract: The present invention relates to variants of Glycoside Hydrolase family 53 galactanases, e.g., variants of the galactanases from strains of Yersinia, Aspergillus, Humicola, Meripilus, Myceliophthora, Thermomyces, Bacillus, Bifidobacterium, Cellvibrio, Clostridium, Pseudomonas, Thermotoga, or Xanthomonas.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: February 5, 2013
    Assignee: Novozymes A/S
    Inventors: Leonardo De Maria, Allan Svendsen, Torben Vedel Borchert, Lars Lehmann Hylling Christensen, Sine Larsen, Carsten Ryttersgaard
  • Publication number: 20120329072
    Abstract: Disclosed herein are methods, systems and kits to measure the presence and/or activity of recombinant polypeptides comprising a modification.
    Type: Application
    Filed: May 18, 2012
    Publication date: December 27, 2012
    Inventors: Alfred Weber, Andrea Engelmaier, Hans-Peter Schwarz
  • Publication number: 20120258470
    Abstract: A mutant hydrolase optionally fused to a protein of interest is provided. The mutant hydrolase is capable of forming a bond with a substrate for the corresponding nonmutant (wild-type) hydrolase which is more stable than the bond formed between the wild-type hydrolase and the substrate. Substrates for hydrolases comprising one or more functional groups are also provided, as well as methods of using the mutant hydrolase and the substrates of the invention. Also provided is a fusion protein capable of forming a stable bond with a substrate and cells which express the fusion protein.
    Type: Application
    Filed: April 18, 2012
    Publication date: October 11, 2012
    Applicant: PROMEGA CORPORATION
    Inventors: Keith V. Wood, Dieter Klaubert, Georgyi V. Los, Robert F. Bulleit, Mark McDougall, Chad Zimprich
  • Publication number: 20120258088
    Abstract: The present disclosure relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistant S. Aureus and VISA.
    Type: Application
    Filed: July 1, 2009
    Publication date: October 11, 2012
    Inventors: Vincent A. Fischetti, Anu Daniel, Chad Euler
  • Publication number: 20120246757
    Abstract: A development of an Artificial SUMO Ligase (ASUL) to increase the ability of Ubc9 to interact with the SUMO target protein, therefore increasing the rate of SUMOylation of the target and a net increase in the total amount of SUMOylated target protein in the cell is described herein. The method of the present invention involves the creation of a protein fusion between a protein domain known to interact with the target protein to be SUMOylated (ID) and the SUMO conjugating enzyme Ubc9. Compositions and methods involving an ASUL comprising a fusion of the N-terminal domain of influenza A virus non-structural protein (NS1) and Ubc9 is also described.
    Type: Application
    Filed: March 22, 2012
    Publication date: September 27, 2012
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: German Rosas-Acosta, Sangita Pal
  • Patent number: 8263353
    Abstract: The present invention provides a method for detecting autoprocessed, secreted PCSK9, a protein involved in cholesterol homeostasis, and for effectively identifying compounds that inhibit autocleavage and secretion from cells. The disclosed method involves the insertion of an epitope tag into a PCSK9 expression construct immediately C-terminal to the pro domain ending at an amino acid residue corresponding to Q152 of human PCSK9. Upon autoprocessing, the epitope tag is exposed and capable of recognition by anti-epitope antibodies or other suitable identification system, allowing for the selective and exclusive identification and/or quantification of processed PCSK9. The present disclosure thus advances the goal of providing enabling technology to the art for the effective identification of therapeutics effective in combating coronary heart disease.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: September 11, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ayesha Sitlani, Timothy S. Fisher, Joseph C. Santoro
  • Patent number: 8236512
    Abstract: The present disclosure relates to methods of developing terpene synthase variants through engineered host cells. Particularly, the disclosure provides methods of developing terpene synthase variants with improved in vivo performance that are useful in the commercial production of terpene products. Further encompassed in the present disclosure are superior terpene synthase variants and host cells comprising such terpene synthase variants.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: August 7, 2012
    Assignee: Amyris, Inc.
    Inventors: Lishan Zhao, Lan Xu, Patrick Westfall, Andrew Main
  • Patent number: 8232080
    Abstract: Described herein are variants of H. jecorina CBH I, a Cel7 enzyme. The present invention provides novel cellobiohydrolases that have improved thermostability and reversibility.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: July 31, 2012
    Assignee: Danisco US Inc.
    Inventors: Anthony Day, Frits Goedegebuur, Peter Gualfetti, Colin Mitchinson, Paulien Neefe, Mats Sandgren, Andrew Shaw, Jerry Stahlberg
  • Patent number: 8202700
    Abstract: A mutant hydrolase optionally fused to a protein of interest is provided. The mutant hydrolase is capable of forming a bond with a substrate for the corresponding nonmutant (wild-type) hydrolase which is more stable than the bond formed between the wild-type hydrolase and the substrate and has at least two amino acid substitutions relative to the wild-type hydrolase. Substrates for hydrolases comprising one or more functional groups are also provided, as well as methods of using the mutant hydrolase and the substrates of the invention. Also provided is a fusion protein capable of forming a stable bond with a substrate and cells which express the fusion protein.
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: June 19, 2012
    Assignee: Promega Corporation
    Inventors: Aldis Darzins, Lance Encell, Tonny Johnson, Dieter Klaubert, Georgyi V. Los, Mark McDougall, Keith V. Wood, Monika G. Wood, Chad Zimprich
  • Patent number: 8182986
    Abstract: Methods and compositions are provided for assaying for enzymes capable of releasing an enzyme donor fragment (ED) conjugated to a nucleic acid strand bonded to a surface. Conveniently, the beads are magnetic allowing segregation of the beads during the determination. Upon addition of enzyme acceptor fragment (EA) and substrate to the assay mixture, the method allows for discrimination between ED free in solution and ED bound to the bead. The complexing of ED and EA provides an active ?-galactosidase enzyme. The method permits the assay of any substance involved in a pathway that can result in a reaction releasing the ED.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: May 22, 2012
    Assignee: Discoverx
    Inventors: Pyare Khanna, Shu-Ling Cheng
  • Publication number: 20120107836
    Abstract: The present invention relates to a kinase labelled at an amino acid naturally present or introduced in the P-loop of said kinase, wherein said labelling is effected at a free thiol or amino group of said amino acid and said label is (a) a thiol- or amino-reactive fluorophore sensitive to polarity changes in its environment; or (b) a thiol-reactive spin label, an isotope or an isotope-enriched thiol- or amino-reactive label, such that said fluorophore, spin label, isotope or isotope-enriched label does not inhibit the catalytic activity and does not interfere with the stability of the kinase. The invention furthermore relates to a method of screening for kinase inhibitors, a method of determining the kinetics of ligand binding and/or of dissociation of a kinase inhibitor and a method of generating mutated kinases suitable for the screening of kinase inhibitors using the kinase of the present invention.
    Type: Application
    Filed: October 13, 2011
    Publication date: May 3, 2012
    Inventors: Daniel Rauh, Jeffrey Raymond Simard
  • Patent number: 8148093
    Abstract: This invention relates to a method for assessing risk of prostate cancer. Specifically, it relates to utilizing both Pro108 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In addition, it is directed to a method for assessing risk of ovarian, colon, breast or stomach cancer utilizing Pro108 or specific antibodies to Pro108. The invention provides isolated anti-prostate, ovarian, colon, breast or stomach cancer antigen (Pro108) antibodies that bind to Pro108 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro108 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro108 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro108 antibodies. The invention encompasses a method of producing the anti-Pro108 antibodies.
    Type: Grant
    Filed: October 3, 2007
    Date of Patent: April 3, 2012
    Assignee: diaDexus, Inc.
    Inventors: Iris Simon, Laura Corral, Charis Lawrenson, Nam Kim, Glenn Pilkington, Robert L. Wolfert
  • Patent number: 8114583
    Abstract: A target and methods for specific binding and inhibition of RNA polymerase from bacterial species are provided, including methods for identifying agents that bind to a bacterial RNA polymerase, and that inhibit an activity of a bacterial RNA polymerase, through interactions with a bacterial RNA polymerase homologous switch-region amino-acid sequence. The methods can include preparation of a reaction solution comprising the compound to be tested and an entity containing a bacterial RNAP homologous switch-region amino-acid sequence, and detection of binding or inhibition. Applications in control of bacterial gene expression, control of bacterial viability, control of bacterial growth, antibacterial chemistry, and antibacterial therapy are also provided.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: February 14, 2012
    Assignee: Rutgers, The State University of New Jersey
    Inventor: Richard H. Ebright
  • Patent number: 8101373
    Abstract: Truncated fragments of the small fragment of ?-galactosidase are provided that have low affinity for the large fragment of ?-galactosidase and provide for robust signals when two fusion proteins are complexed due to the binding of the proteins to which the ?-galactosidase fragments are fused. The truncated fragments do not interfere with the complexing of the two proteins and allow for the two proteins to function and be responsive to candidate compounds that affect complex formation.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: January 24, 2012
    Assignee: Discoverx Corporation
    Inventors: Thomas Scott Wehrman, Keith R. Olson
  • Publication number: 20120003667
    Abstract: Methods for measuring hetero- and homodimerization of HIV reverse transcriptase (HIV RT) are provided using pairs of tagged probes and cleaving probes. The methods can be used, for example, to screen for modulators of HIV RT dimerization. Also provided are methods of determining whether a compound modulates HIV RT. Further provided are methods of determining whether a compound modulates formation of a complex between a p66 and p51, p66 and p66, or p51 and p55 subunits polypeptides of HIV RT.
    Type: Application
    Filed: June 16, 2008
    Publication date: January 5, 2012
    Inventors: Soumi Gupta, Rajiv Dua, Douglas McCann